First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Hypothalamic obesity is a complex condition that doesn’t always respond to traditional weight loss methods. Medications, hormonal therapy, and surgery may be necessary to see results. Hypothalamic ...

Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...

This is due to epigenetic components: microRNA, histone and DNA methylation, gene mutations that alter the expression and production of the neurotrophic factor BDNF, which interacts with the receptors ...

First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity ---- European Commission grants authorization in adults ...